February 2019
Twitter logo for website footers 2

2018 Speakers

Expand/Collapse

Tom Holdich
Head, Global Medical Affairs & EU Clinical Development
Adaptimmune

Day One

Wednesday 21st February, 2018

15.00 | Running Multi Solid Tumor Trials Effectively

Owain Millington
Development Manager
TC Biopharm

Heidi Hagen
Chief Strategy Officer & Co-founder
Vineti

Day One

Wednesday 21st February, 2018

15.30 | Early-Stage Innovations for Long-Term Success

Jenny Marlowe
Head of Preclinical Development
bluebird bio

Day One

Wednesday 21st February, 2018

17.00 | Approaches for understanding and derisking normal tissue target expression for chimeric antigen receptor (CAR) T cell therapies

Laurent Poirot
Head of Early Discovery
Cellectis

Day One

Wednesday 21st February, 2018

17.30 | Panel: Mitigating Safety Risks of CAR-TCR Therapies: Ensuring Durability, Expansion and Persistence

10.00 | New Frontier CAR-T and TCR technologies for Therapeutic Development

Simon Lacey
Director, Translational & Correlative Studies Laboratory
University of Pennsylvania

Day One

Wednesday 21st February, 2018

17.30 | Panel: Mitigating Safety Risks of CAR-TCR Therapies: Ensuring Durability, Expansion and Persistence

Gert Boschman
Scientific Affairs Director Europe
BD Biosciences

Day Two

Thursday 22nd February, 2018

11.30 | BD Solutions in Cell Therapy Development and Production

Ali Mohamed
Vice President, CMC
Immatics

Day Two

Thursday 22nd February, 2018

12.00 | Development of TCR-engineered T Cell Therapies for solid tumors: From Target to T Cell Product

Mark McCall
Centre for Biological Engineering
Loughborough University

Morning Workshop

Tuesday 20th February 2018

09.00 |

Accessibility and Affordability: How Do We Ensure This?

Detlev Parow
Head, Care Management Development
DAK-Gesundheit

Morning Workshop

Tuesday 20th February 2018

09.00 |

Accessibility and Affordability: How Do We Ensure This?

Grace Hampson
Senior Economist
The Office of Health Economics

Morning Workshop

Tuesday 20th February 2018

09.00 |

Accessibility and Affordability: How Do We Ensure This?

Pierre Heimendinger
VP Pharmaceutical Development
TxCell

Day Two

Thursday 22nd February, 2018

14.30 | Development of First Manufacturing Process to Produce CAR-Treg Cells for Clinical Use

Christopher Bunker
Vice President, Business Development
ACD

Day One

Wednesday 21st February, 2018

12.30 | RNAscope® Platform: Enabling Preclinical and Clinical T Cell Therapy PK/PD Analysis, Target Engagement and Biomarker Analysis

Helen Tayton-Martin
CBO
Adaptimmune

Dr. Helen Tayton‑Martin has served as Adaptimmune’s Chief Operating Officer since July 2008 and is one of Adaptimmune’s co-founders. She is responsible for business development and commercial activities, including Adaptimmune’s strategic partnership with GSK. Dr. Tayton-Martin has 23 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She is a co-founder of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy from 2005 to 2008. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

Chris Haqq
CSO
Atara Biotherapeutics

Dr. Christopher Haqq is the EVP, Chief Scientific Officer, and joined Atara Biotherapeutics in September 2012. He brings 20 years of clinical, academic and drug development experience from biopharma companies large and small. He was recently Vice President for Clinical Research and Development at Cougar Biotechnology and Johnson & Johnson’s Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Previously at Amgen, he led early development studies of the anti-insulin like growth factor type 1 receptor AMG 479 (ganitumab) antibody. He has served as medical monitor for more than 10 clinical trials and has contributed to drug development programs for a wide range of molecules. Chris has worked closely with the European Medicines Agency, the U.S. Food and Drug Administration and other global regulatory agencies–filing IND applications, new drug applications, special protocol assessments and their international equivalents. Earlier in his career, Chris practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. In his post-graduate training, also at UCSF, he served as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Chris completed his M.D. and Ph.D. at Harvard Medical School and his B.S. at Stanford University. He is board certified in Medical Oncology and Internal Medicine. Chris is an inventor of several patents and an author of more than 50 medical publications. In his free time, he enjoys astronomy and photography.

Day One

Wednesday 21st February, 2018

13.00 | Expanding Off-the-Shelf T-Cell Therapy Applications in Cancer, Autoimmune Diseases and Serious Viral Infections

Jens Hasskarl
Senior Director, Medical, Clinical Research & Development
Celgene

Day One

Wednesday 21st February, 2018

17.30 | Panel: Mitigating Safety Risks of CAR-TCR Therapies: Ensuring Durability, Expansion and Persistence

16.30 | Overcoming Mechanisms of Toxicity and Resistance

Representative to be confirmed, Cellectis

Martina Schussler-Lenz
Chair CAT
EMA

Afternoon Workshop

Tuesday 20th February 2018

13.00 |

Navigating the Regulatory Minefield: From Trials to Approval

Lothar Germeroth
SVP, Managing Director
Juno Therapeutics

Lothar Germeroth is our Senior Vice President, Managing Director Juno Therapeutics GmbH, and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of experience in the field of biotechnology. Most recently, Dr. Germeroth served as the CEO at IBA GmbH and the COO at Stage Cell Therapeutics GmbH, and served eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos Biotechnology AG in Switzerland. Dr. Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel Prize Laureate Professor Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt.

Day Two

Thursday 22nd February, 2018

10.00 | Creating a Highly Innovative Cell Production Platform for a CDI9 CAR in Lymphoma

15.00 | Panel: Logistics, Scheduling and Supply Chain Management

Jian Irish
SVP, Supply Chain
Kite Pharma

Dr. Jian Irish, Ph.D. , has been Senior Vice President of Supply Chain at Kite Pharma, Inc. since December 1, 2016. Dr. Irish established her career in the biopharmaceutical industry through various global leadership roles. She joins Kite from Sanofi, where she served as the Vice President of Biologics Strategic Supply, Sourcing and Partnerships. She served as Vice President of Biologics Product Development Technology Transfer at Sanofi. In these roles, Dr. Irish oversaw the strategy and execution of the Biologics supply chain and technical transfer processes to scale up Sanofi Biological operations. Prior to Sanofi, Dr. Irish was the Executive Director, General Manager of Japan Asia Pacific Supply Chain at Amgen as well as the Executive Director, Global Head of Contract Manufacturing where Dr. Irish made a critical impact in the commercialization of Vectibix, Xgeva and Enbrel. Dr. Irish holds a Bachelor of Science in Chemical Engineering from East China University of Science and Technology in Shanghai, China, a Master of Science and Ph.D. in Pharmaceutical Sciences from Chiba University in Chiba, Japan and a Master of Business Administration from the Anderson School of Management at University of California, Los Angeles

Day Two

Thursday 22nd February, 2018

09.30 | Developing a Supply Chain that is Tailored for Personalized Cell Therapy

15.00 | Panel: Logistics, Scheduling and Supply Chain Management

John Maher
CSO
Leucid Bio

Day One

Wednesday 21st February, 2018

09.00 | T4 immunotherapy: Phase I Trial of Intra-Tumoural CAR-T Cell Therapy in Head and Neck Cancer

Dolores Schendel
CEO
Medigene

  Prof. Dolores J. Schendel holds the position of CEO/CSO of Medigene AG, a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried, Germany. In addition, she is Managing Director of Medigene Immunotherapies GmbH, a subsidiary of Medigene that she and coworkers founded as a spin-off of the Helmholtz Center Munich in 2013, and acquired by Medigene in January 2014. Prof. Schendel served from 1998-2014 as Director of the Institute of Molecular Immunology of the Helmholtz-Center Munich - German Research Center for Environmental Health. She also holds a professorship in immunology at the Ludwig Maximilian University of Munich since 1986.

Day One

Wednesday 21st February, 2018

12.00 | Transitioning CAR-T success to TCR-T success

Michael Papadimitrious
Product Manager for Engineered T Cells
Miltenyi Biotec

Day Two

Thursday 22nd February, 2018

13.30 | Automated Manufacturing of Clinical-Scale Gene-Engineered T Cells Using the CliniMACS Prodigy

Oezlem Anak
Senior Global Clinical Programme Head, Cell & Gene Therapies
Novartis

Özlem is Senior Global Clinical Program Head at Novartis for CD19 CAR-T compound Kymriah (Tisagenlecleucel- CTL019).  She has been working in oncology development for about 20 years in non-profit academic organizations such as EORTC (European Organization of Research and Treatment of Cancer) and in Pharma industries, Roche and Novartis. Prior to cell and gene arena, she had wide drug development experience in oncology including  antibody and small molecule developments in several indications. She is currently leading the clinical development of Kymriah in lymphoma indications. She is  based in Basel Switzerland.

Day One

Wednesday 21st February, 2018

14.30 | Kymriah: Sharing Clinical Expertise and Experiences from the First Approved CAR-T Product

Jessica Hartmann
Research Unit for Molecular Biotechnology and Gene Therapy
Paul Ehrlich Institute

Day Two

Thursday 22nd February, 2018

14.00 | Improving CAR Gene Delivery by T-Cell Targeted Lentiviral Vectors

Thierry Wurch
Director. Immuno-Oncology External Research & Innovation
Servier

Dr Thierry WURCH, Director – Immuno-oncology Discovery Research – Therapeutic Innovation Pole in Oncology – Institut de Recherches SERVIER Dr. Wurch completed a Ph.D in Molecular and Cellular Biology at the University Louis Pasteur (Strasbourg, FR, 1992), followed by a post-doctoral training at the University of Ghent (BE). Back to France in 1994, he raised a molecular biology laboratory at the Pierre FABRE Research Center in Castres (FR). In 2003, he moved to the Centre d’Immunologie Pierre FABRE where he established a Molecular and Cellular Biology Department dedicated to molecular pharmacology and protein and antibody engineering. Since September 2011, he leads the immunotherapy discovery research programs at the Institut de Recherches Servier, the largest independent French Parma group. He is currently member of the Editorial board of mAbs (Landes Bioscience) and Distinguished Advisor of The Antibody Society. He is co-author of more than 90 publications. In 2013, Thierry Wurch, was ranked #33 amongst the Top 50 global antibody industry influencers.

Day Two

Thursday 22nd February, 2018

10.30 | Creating a Universal Donor based Cell Therapy

Elisa Kieback
CEO
T-Knife

Day One

Wednesday 21st February, 2018

09.30 | How to Generate Optimal-Affinity TCRs for the Clinic?

Michael Leek
CEO
TC Biopharm

Michael has 27 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.

Day One

Wednesday 21st February, 2018

11.30 | Formulation of Gamma-Delta CAR-T Products: A Novel Approach for Solid Tumours